In vitro antibacterial activity of NB-003 against Propionibacterium acnes

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 9, 2011, Pages 4211-4217

  Pannu, J ^a   McCarthy, A ^a   Martin, A ^a   Hamouda, T ^a   Ciotti, S ^a   Ma, L ^a   Sutcliffe, J ^a,b   Baker Jr , J R ^a  

^a NanoBio Corporation   (United States)

^b Tetraphase Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ACNE AGENT; BENZOYL PEROXIDE; CLEARASIL; CLINDAMYCIN; EDETIC ACID; ERYTHROMYCIN; NB 003; PERSA GEL 10; PROACTIV; SALICYLIC ACID; TETRACYCLINE; UNCLASSIFIED DRUG; WATER OIL CREAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; FRACTIONAL BACTERICIDAL CONCENTRATION; GEL; IN VITRO STUDY; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NANOEMULSION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROPIONIBACTERIUM ACNES;

ANTI-BACTERIAL AGENTS; CLINDAMYCIN; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; PROPIONIBACTERIUM ACNES; TETRACYCLINE;

EID: 80051809583     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00561-11     Document Type: Article

References (65)

1. Bogdanovich, T., L M Ednie, S. Shapiro, and P C Appelbaum. 2005. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:4210-4219. (Pubitemid 41400966)
2. Boivin, G., N. Goyette, and J. Sutcliffe. 2008. A novel nanoemulsion active against acyclovir (ACV)- and foscarnet (FOS)-resistant herpes simplex virus (HSV) 1 and 2. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. V-3538.
3. Bonapace, C R, J A Bosso, L V Friedrich, and R L White. 2002. Comparison of methods of interpretation of checkerboard synergy testing. Diagn. Microbiol. Infect. Dis. 44:363-366. (Pubitemid 36120715)
4. Bowe, W P, and A R Shalita. 2008. Effective over-the-counter acne treatments. Semin. Cutan. Med. Surg. 27:170-176.
5. Ciotti, S., R. Eisma, L. Ma, and J R Baker, Jr. 2008. Novel nanoemulsion NB-001 permeates skin by the follicular route. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-1898.
6. Ciotti, S., R. Eisma, L. Vengroff, L. Ma, and J R Baker, Jr. 2008. Mechanism of skin penetration and distribution of a novel antimicrobial nanoemulsion. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-2135.
7. CLSI. 2007. Methods for antimicrobial susceptibility testing of anaerobic bacteria, 7th ed. Approved standard M11-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
8. CLSI. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline M26-A. Clinical and Laboratory Standards Institute, Wayne, PA.
9. Coates, P., et al. 2002. Prevalence of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distribution study. Br. J. Dermatol. 146:840-848. (Pubitemid 34539195)
10. Cunliffe, W J, K T Holland, R. Bojar, and S F Levy. 2002. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin. Ther. 24:1117-1133. (Pubitemid 34833234)
11. Davies, T A, G A Pankuch, B E Dewasse, M R Jacobs, and P C Appelbaum. 1999. In vitro Development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:1177-1182. (Pubitemid 29214743)
12. Del Rosso, J Q 2007. Highlights from the latest acne treatment guidelines. Skin Aging 15:84-88.
13. Dhawan, S S 2009. Comparison of 2 clindamycin 1%-benzoyl peroxide 5% topical gels used once daily in the management of acne vulgaris. Cutis 83:265-272.
14. Draelos, Z D, V. Callender, C. Young, and S S Dhawan. 2008. The effect of vehicle formulation on acne medication tolerability. Cutis 82:281-284.
15. Eady, E A, et al. 1996. The effects of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant propionibacteria. Br. J. Dermatol. 134:107-113. (Pubitemid 26030998)
16. Farca, A M, P. Nebbia, and G. Re. 1994. Potentiation of antibiotic activity by EDTA-tromethamine against three clinically isolated Gram-positive resistant bacteria. An in vitro investigation. Vet. Res. Commun. 18:1-6. (Pubitemid 24176530)
17. Fritsche, T., R. Biedenhach, R. Jones, and J. Sutcliffe. 2008. Antimicrobial activity of nanoemulsions tested against seven Gram-negative species. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-3945.
18. Gloor, M., B. Schorch, and U. Hoeffler. 1979. The feasibility of replacing antibiotics by quaternary ammonium compounds in topical antimicrobial acne therapy. Arch. Dermatol. Res. 265:207-212. (Pubitemid 9210488)
19. Hamouda, T, and J R Baker, Jr. 2000. Antimicrobial mechanism of action of surfactant lipid preparations in enteric Gram-negative bacilli. J. Appl. Microbiol. 89:397-403.
20. Hamouda, T., et al. 1999. A novel surfactant nanoemulsion with broadspectrum sporicidal activity against Bacillus species. J. Infect. Dis. 180:1939-1949.
21. Hamouda, T., et al. 2001. A novel surfactant nanoemulsion with a unique non-irritant topical antimicrobial activity against bacteria, enveloped viruses and fungi. Microbiol. Res. 156:1-7. (Pubitemid 32430537)
22. Hart, J R 1984. Chelating agents as preservative potentiators, p. 54-58. In J. J. Kabara (ed.), Cosmetic and drug preservation: principles and practices. Marcell Dekker, New York, NY.
23. Heller, S., L. Kellenberger, and S. Shapiro. 2007. Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic. Antimicrob. Agents Chemother. 51:1956-1961. (Pubitemid 46903079)
24. Jarrat, M., M M Ijzerman, M R Flack, and J J R Baker. 2008. Safety, tolerability and pharmacokinetics of NB-001 in a phase 2 dose ranging trial in subjects with recurrent herpes labialis. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. V-3539.
25. Jelvehgari, M., M R Siahi-Shadbad, S. Azarmi, G P Martin, and A. Nokhodchi. 2006. The microsponge delivery system of benzoyl peroxide: Preparation, characterization and release studies. Int. J. Pharm. 308:124-132. (Pubitemid 43097243)
26. Jones, T., M. Flack, M M Ijzerman, and J R Baker, Jr. 2008. Safety, tolerance, and pharmacokinetics of topical nanoemulsion (NB-002) for the treatment of onychomycosis. J. Am. Acad. Dermatol. 58:AB83.
27. Jones, T., M. Flack, L. Stanberry, and J R Baker, Jr. 2008. Safety, tolerance, pharmacokinetics, and efficacy of topical nanoemulsion (NB-001) for the treatment of herpes labialis. J. Am. Acad. Dermatol. 58:AB93.
28. Kalchayanand, N., M B Hanlin, and B. Ray. 1992. Sublethal injury makes Gram-negative and resistant Gram-positive bacteria sensitive to the bacteriocins, pediocin AcH and nisin. Lett. Appl. Microbiol. 15:239-243.
29. Kosowska, K., et al. 2005. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49:1932-1942. (Pubitemid 40631609)
30. Kosowska-Shick, K., et al. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769. (Pubitemid 43190997)
31. Lambert, R J W, G W Hanlon, and S P Denye. 2004. The synergistic effect of EDTA/antimicrobial combinations on Pseudomonas aeruginosa. J. Appl. Microbiol. 96:244-253. (Pubitemid 38223550)
32. Leyden, J J 2002. Effect of topical benzoyl peroxide/clindamycin versus topical clindamycin and vehicle in the reduction of Propionibacterium acnes. Cutis 69:475-480. (Pubitemid 41766298)
33. Leyden, J J, et al. 2001. Comparison of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and vehicle gel in the treatments of acne vulgaris. Am. J. Clin. Dermatol. 2:33-39. (Pubitemid 32405892)
34. Leyden, J J, J Q Del Rosso, and G F Webster. 2009. Clinical considerations in the treatment of acne vulgaris and other inflammatory skin disorders: A status report. Dermatol. Clin. 27:1-15.
35. Leyden, J J, J G Hickman, M T Jarratt, D M Stewart, and S F Levy. 2001. The efficacy and safety of a combination benzoyl peroxide/clindamycin topical gel compared with benzoyl peroxide alone and a benzoyl peroxide/erythromycin combination product. J. Cutan. Med. Surg. 5:37-42. (Pubitemid 32588330)
36. Leyden, J J, R R Marples, O H Mills, Jr., and A M Kligman. 1973. Gram-negative folliculitis-a complication of antibiotic therapy in acne vulgaris. Br. J. Dermatol. 88:533-538.
37. Leyden, J J, K J McGinley, O H Mills, and A M Kligman. 1975. Age-related changes in the resident bacterial flora of the human face. J. Investig. Dermatol. 65:379-381.
38. Leyden, J J, K J McGinley, O H Mills, and A M Kligman. 1975. Propionibacterium levels in patients with and without acne vulgaris. J. Investig. Dermatol. 65:382-384.
39. Leyden, J J, M. Wortzman, and E K Baldwin. 2008. Antibiotic-resistant Propionibacterium acnes suppressed by a benzoyl peroxide cleanser 6%. Cutis 82:417-421.
40. Lu, G W, et al. 2009. Comparison of artificial sebum with human and hamster sebum samples. Int. J. Pharm. 367:37-43.
41. Myc, A., T. Vanhecke, J J Landers, T. Hamouda, and J R Baker, Jr. 2002. The fungicidal activity of novel nanoemulsion (X8W60PC) against clinically important yeast and filamentous fungi. Mycopathologia 155:195-201. (Pubitemid 36317519)
42. Nagai, K., et al. 2000. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 44:2740-2746.
43. Nagai, T, and S. Oita. 2004. Anti-Helicobacter pylori activity of EDTA. J. Gen. Appl. Microbiol. 50:115-118. (Pubitemid 39117305)
44. Oprica, C., et al. 2004. Antibiotic-resistant Propionibacterium acnes on the skin of patients with moderate to severe acne in Stockholm. Anaerobe 10:155-164. (Pubitemid 38789116)
45. Oprica, C, and C E Nord. 2005. European surveillance study on the antibiotic susceptibility of Propionibacterium acnes. Clin. Microbiol. Infect. 11:204-213. (Pubitemid 40352767)
46. Pankuch, G A, S A Jueneman, T A Davies, M R Jacobs, and P C Appelbaum. 1998. In vitro selection of resistance to four beta-lactams and azithromycin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2914-2918. (Pubitemid 28501225)
47. Pannu, J., S. Ciotti, R. Eisma, L. Ma, and J. Sutcliffe. 2009. In vitro susceptibility of Propionibacterium acnes and skin permeation of NB00X formulations. Abstr. 69th Annu. Meet. Soc. Investigat. Dermatol., abstr. 616.
48. Pannu, J., et al. 2009. NB-002, a novel nanoemulsion with broad antifungal activity against dermatophytes, other filamentous fungi, and Candida albicans. Antimicrob. Agents Chemother. 53:3273-3279.
49. Pannu, J., et al. 2008. A novel nanoemulsion with anti-dermatophyte activity. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. M-2134.
50. Pannu, J., A. McCarthy, A. Martin, and J. Sutcliffe. 2009. Susceptibility of Propionibacterium acnes in the presence of sebum to NB-003 formulations, abstr. P106. Abstr. 2009 Summer Acad. Meet. Am. Acad. Dermatol.
51. Pfaller, M A, D J Sheehan, and J H Rex. 2004. Determination of fungicidal activities against yeasts and molds: Lessons learned from bactericidal testing and the need for standardization. Clin. Microbiol. Rev. 17:268-280. (Pubitemid 38534030)
52. Roche Laboratories. 2010. Accutane (isotretinoin) drug description facts. Roche Laboratories, Nutley, NJ.
53. Ross, J I, E A Eady, E. Carnegie, and J H Cove. 2002. Detection of transposon Tn5432-mediated macrolide-lincosamide-streptogramin B (MLSB) resistance in cutaneous propionibacteria from six European cities. J. Antimicrob. Chemother. 49:165-168. (Pubitemid 34100661)
54. Ross, J I, et al. 2003. Antibiotic-resistant acne: Lessons from Europe. Br. J. Dermatol. 148:467-478. (Pubitemid 36461325)
55. Smith, M A, P. Alperstein, K. France, E M Vellozzi, and H D Isenberg. 1996. Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test. J. Clin. Microbiol. 34:1024-1026. (Pubitemid 26093701)
56. Stern, R S 2000. Medication and medical service utilization for acne 1995-1998. J. Am. Acad. Dermatol. 43:1042-1048.
57. Strauss, J S, et al. 2007. Guidelines of care for acne vulgaris management. J. Am. Acad. Dermatol. 56:651-663. (Pubitemid 46400177)
58. Sutcliffe, J., D. Biedenbach, R. Jones, and T. Fritsche. 2008. Novel nanoemulsion antimicrobials tested against nine Gram-positive species. Abstr. 48th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F1-3944.
59. Tzellos, T., V. Zampeli, E. Makrantonaki, and C C Zouboulis. 2011. Treating acne with antibiotic-resistant bacterial colonization. Expert Opin. Pharmacother. 12:1233-1247.
60. Vaara, M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
61. Valiveti, S, and G W Lu. 2007. Diffusion properties of model compounds in artificial sebum. Int. J. Pharm. 345:88-94. (Pubitemid 350087546)
62. Valiveti, S., J. Wesley, and G W Lu. 2008. Investigation of drug partition property in artificial sebum. Int. J. Pharm. 346:10-16. (Pubitemid 350101987)
63. Verma, P. 2007. Methods for determining bactericidal activity and antimicrobial interactions: Synergy testing, time-kill curves, and population analysis, p. 275-298. In R. Schwalbe, L. Steele-Moore, and A. C. Goodwin (ed.), Antimicrobial susceptibility testing protocols. CRC Press, Boca Raton, FL.
64. Weinberg, J M 2006. The utility of benzoyl peroxide in hydrophase base (Brevoxyl) in the treatment of acne vulgaris. J. Drugs Dermatol. 5:344-349.
65. Zhang, L., et al. 2008. Nanoparticles in medicine: Therapeutic applications and developments. Clin. Pharmacol. Ther. 83:761-769. (Pubitemid 351556021)